论文部分内容阅读
目的:研究羟基脲联合小剂量肠溶阿司匹林治疗真性红细胞增多症的疗效及对凝血功能的影响。方法:选取2012年1月~2014年12月在我院接受诊治的60例门诊或住院真性红细胞增多症患者作为研究对象,根据随机数表法分为对照组、观察组,各30例。给予对照组患者羟基脲治疗,给予观察组患者羟基脲联合小剂量肠溶阿司匹林治疗。比较两组患者的凝血功能指标(PT、APTT、FIB、TT)、血象指标(Hb、RBC、PLT、HCT)及疗效。结果:治疗前,两组凝血功能指标(PT、APTT、FIB、TT)差异无统计学意义;治疗后,两组患者的PT、APTT、FIB、TT水平均低于治疗前,且观察组低于对照组,差异有统计学意义;治疗前,两组Hb、RBC、PLT、HCT指标差异无统计学意义;治疗后,两组患者Hb、RBC、PLT、HCT水平均低于治疗前,且观察组低于对照组,差异有统计学意义;观察组治疗总缓解率(96.7%)高于对照组(73.3%),差异有统计学意义。结论:羟基脲联合小剂量肠溶阿司匹林能有效改善真性红细胞增多症患者凝血功能,缓解临床症状,减少出血风险。
Objective: To study the efficacy of hydroxyurea in combination with low-dose enteric-coated aspirin in the treatment of polycythemia vera and its effect on the coagulation function. Methods: Sixty outpatients or hospital polyclinic inpatients admitted to our hospital from January 2012 to December 2014 were selected as study subjects and divided into control group and observation group with 30 cases in each group according to random number table. Patients in the control group were treated with hydroxyurea, and patients in the observation group were treated with hydroxyurea in combination with low-dose enteric-coated aspirin. The coagulation parameters (PT, APTT, FIB, TT), blood parameters (Hb, RBC, PLT, HCT) and the curative effect were compared between the two groups. Results: Before treatment, there was no significant difference in coagulation function index (PT, APTT, FIB, TT) between the two groups after treatment; PT, APTT, FIB and TT levels in both groups were lower than before treatment There was no significant difference in Hb, RBC, PLT and HCT between the two groups before treatment, after treatment, the levels of Hb, RBC, PLT and HCT in both groups were lower than those before treatment The observation group was lower than the control group, the difference was statistically significant; observation group, the total response rate was 96.7% higher than the control group (73.3%), the difference was statistically significant. Conclusion: Hydroxyurea combined with low-dose enteric-coated aspirin can effectively improve coagulation function, alleviate clinical symptoms and reduce the risk of bleeding in patients with polycythemia vera.